Alnylam Pharma (ALNY) Tops Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity
February 7, 2019 4:00 PM ESTAchieved Fourth Quarter 2018 ONPATTRO® Global Net Product Revenues of $12.1 Million, with Over 200 Patients on Commercial Product in U.S. and EU as of Year-End 2018
Obtained Regulatory Alignment on APOLLO-B Phase 3 Study of Patisiran in ATTR Amyloidosis with Cardiomyopathy and Initiated HELIOS-A Phase 3 Study to Advance Vutrisiran to Market, Supporting Plan for Sustained and Continuous Growth of ATTR Franchise
Advanced Additional Phase 3 Programs, Including Givosiran, with Rolling Submission of New Drug Application (NDA) Initiated and Topline ENVISION Phase 3 Results Expected in March, and Lumasiran, with ILLUMINATE-A Phase 3 Study Initiated
Maintained Strong Balance... More
